Overview

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to administer a combined oral contraceptive (ethinyl estradiol and norgestimate) with the HIV treatment of atazanavir and ritonavir to healthy females in order to assess if the concentrations of the oral contraceptive change. The safety of this treatment regimen will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Atazanavir Sulfate
Contraceptive Agents
Contraceptives, Oral
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Ethinyl Estradiol
Fluoroquinolones
Moxifloxacin
Norgestimate
Norgestimate, ethinyl estradiol drug combination
Norgestrel
Polyestradiol phosphate
Ritonavir